Viewing Study NCT07326592

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2026-03-26 @ 3:15 PM

Ignite Modification Date: 2026-03-30 @ 3:05 AM

Study NCT ID: NCT07326592

Status: NOT_YET_RECRUITING

Last Update Posted: 2026-03-06

First Post: 2026-01-07

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)

Sponsor: CSL Behring

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module